Blueprint Medicines
Blueprint Medicines Corporation, headquartered in the United States, is a pioneering biotechnology company focused on targeted therapies for genomically defined cancers, rare diseases, and cancer immunotherapy. Founded in 2008, the company has achieved significant milestones, including the development of innovative treatments that address unmet medical needs. With a strong emphasis on precision medicine, Blueprint Medicines offers a portfolio of unique products, including targeted therapies that inhibit specific genetic mutations. This approach not only enhances treatment efficacy but also minimises side effects, setting the company apart in the competitive biotech landscape. Recognised for its commitment to advancing patient care, Blueprint Medicines has established a prominent market position, driven by its robust pipeline and strategic collaborations. The company continues to lead the way in transforming the treatment landscape for patients with complex diseases.
DitchCarbon Score
How does Blueprint Medicines's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Education Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Blueprint Medicines's score of 23 is higher than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Blueprint Medicines's reported carbon emissions
Blueprint Medicines, headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. Without emissions figures, it is challenging to assess their carbon footprint or the scope of their emissions (Scope 1, 2, or 3). However, the company is likely aware of the growing importance of climate commitments within the pharmaceutical industry, which is increasingly focused on sustainability and reducing environmental impact. As the industry evolves, it is expected that Blueprint Medicines will align with best practices and set measurable climate goals in the future.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Blueprint Medicines is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
